Stockscreener 앱 받기
19.20
4.83%
-0.975
시간 외 거래:
19.19
-0.005
-0.03%
전일 마감가:
$20.17
열려 있는:
$19.74
하루 거래량:
369.00K
Relative Volume:
1.48
시가총액:
$1.04B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-20.39%
1개월 성능:
-12.59%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$18.73
$21.19
1주일 범위
$18.73
$24.15
52주 변동 폭
$18.33
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
명칭
Bicara Therapeutics Inc
전화
617-785-8308
주소
245 MAIN STREET, CAMBRIDGE
BCAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| BCAX | 19.20 | 1.04B | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap DownShould You Sell? - MarketBeat
FY2024 EPS Estimates for BCAX Cut by Cantor Fitzgerald - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 6.2%Here's Why - MarketBeat
Bicara Therapeutics Reports Strong IPO and Clinical Advancements - TipRanks
Bicara Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Bicara Therapeutics: Newly Minted Upsized IPO With Positive Early Data (NASDAQ:BCAX) - Seeking Alpha
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Bicara's $362M IPO Success Powers Cancer Drug Trial with 64% Response Rate | BCAX Stock News - StockTitan
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference - The Manila Times
Bicara Therapeutics (NASDAQ:BCAX) Rating Increased to Strong-Buy at RODMAN&RENSHAW - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $43.33 Consensus Target Price from Analysts - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Upgraded to "Strong-Buy" at RODMAN&RENSHAW - MarketBeat
Bicara Therapeutics stock gets Buy rating from H.C. Wainwright on asset - Investing.com
Rodman & Renshaw Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - MarketBeat
Biocon Stole Licensed Cancer Biotech to Fuel Spinoff, Suit Says - Bloomberg Law
Morgan Stanley spotlights 10 small-cap stocks with at least 50% upside - Kursiv Media
Bicara Therapeutics (NASDAQ:BCAX) Trading Up 7.9%Should You Buy? - MarketBeat
Balance Sheet Breakdown: Bicara Therapeutics Inc. (BCAX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
In the Green: Bicara Therapeutics Inc. (BCAX) Closes at 19.00, Up/Down -6.40 from Previous Day - The Dwinnex
Bicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week LowWhat's Next? - MarketBeat
Down rounds don’t aid post-IPO performance - BioCentury
Bicara shares initiated with Buy on cancer drug potential By Investing.com - Investing.com South Africa
Bicara stock poised for growth with late-stage transition, Morgan Stanley optimistic - Investing.com
Bicara Therapeutics stock sees upside with lead drug potential, says Stifel - Investing.com
Bicara shares initiated with Buy on cancer drug potential - Investing.com India
Cantor Fitzgerald starts Bicara Therapeutics with Overweight rating - Investing.com
Cantor Fitzgerald starts Bicara Therapeutics with Overweight rating By Investing.com - Investing.com South Africa
Bicara Therapeutics stock sees upside with lead drug potential, says Stifel By Investing.com - Investing.com South Africa
Three startups aim to raise $400 mln as US biotech IPOs gain traction - Reuters
Bicara Leads Trio of US Biotech IPOs Raising $703 Million - MSN
Market Update: Bicara Therapeutics Inc. (BCAX) Sees Negative Movement, Closing at 24.43 - The Dwinnex
Bicara Therapeutics, Adecoagro, and More Stocks See Action From Activist Investors - MSN
Kiran Mazumdar-Shaw’s niece makes debut at Nasdaq as Bicara Therapeutics goes public - The Financial Express
With IPO, have the capital and resources for clinical studies: Bicara CEO - The Economic Times
Bicara Therapeutics Rings the Opening Bell - Nasdaq
Bicara Therapeutics Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Biotech IPO Shares Climb in Debuts After Deals Upsized - MSN
TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc - GuruFocus.com
James E. Flynn Buys 70,000 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock - Defense World
Upstream Bio goes public amid spate of IPOs - The Pharma Letter
Ra Capital Management, L.P. Purchases 1,833,000 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock - Defense World
Ra capital executives buy Bicara Therapeutics shares for $32.99m By Investing.com - Investing.com Canada
Ra capital executives buy Bicara Therapeutics shares for $32.99m - Investing.com India
FMR LLC Acquires New Stake in Bicara Therapeutics Inc - Yahoo Finance
Deerfield entities buy Bicara Therapeutics shares worth $1.26m By Investing.com - Investing.com Australia
Deerfield entities buy Bicara Therapeutics shares worth $1.26m - Investing.com
Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity - Yahoo Finance
MBX, Zenas And Bicara IPOs Generate Big First Day Returns, But Will They Last? - Scrip
Bicara Therapeutics Inc (BCAX) 재무 분석
Bicara Therapeutics Inc (BCAX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):